Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Capital Expenditures (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Capital Expenditures for 10 consecutive years, with -$62000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 138.04% to -$62000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2025, down 28.57% year-over-year, with the annual reading at $5.0 million for FY2025, 28.57% down from the prior year.
  • Capital Expenditures for Q4 2025 was -$62000.0 at Ultragenyx Pharmaceutical, down from $4.0 million in the prior quarter.
  • The five-year high for Capital Expenditures was $66.1 million in Q3 2022, with the low at -$19.0 million in Q2 2023.
  • Average Capital Expenditures over 5 years is $12.3 million, with a median of $3.6 million recorded in 2024.
  • The sharpest move saw Capital Expenditures skyrocketed 443.92% in 2021, then tumbled 145.66% in 2022.
  • Over 5 years, Capital Expenditures stood at $16.0 million in 2021, then skyrocketed by 68.06% to $27.0 million in 2022, then tumbled by 95.06% to $1.3 million in 2023, then crashed by 87.77% to $163000.0 in 2024, then crashed by 138.04% to -$62000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at -$62000.0, $4.0 million, and -$544000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.